Combined treatment with HDAC10 and FLT3 inhibitors (or chemotherapy) synergistically reduced the viability of FLT3-ITD AML models and of cells from FLT3-ITD relapsed patients. This evidence concerns the gene HDAC10 and acute myeloid leukemia.